BioCentury
ARTICLE | Company News

Altor BioScience, NantKwest deal

October 10, 2016 7:00 AM UTC

Altor and NantKwest partnered to co-develop cancer therapies using Altor’s ALT-803 and ALT-801 in combination with NantKwest’s natural killer (NK) cell therapy platforms. ALT-803, an IL-15 mutant ag...